Insider filing · IMVT
Andrew J. Fromkin
Director
profile →
Immunovant, Inc.
IMVT · Healthcare · 33 filings in 24 months
ticker →
Andrew J. Fromkin sold $448K of Immunovant (IMVT)
Executed Dec 1 2025, disclosed Dec 3 2025, 2 days later.
Value, as filed
$448K
19,351 sh × $23.14
Executed
Dec 1 2025
the trade date, as filed
Disclosed
Dec 3 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
AFAndrew J. Fromkin (Director) filed 2 Form 4 reports in the trailing twelve months (0 purchases, 2 sales), most often in Immunovant, Inc. (IMVT). The largest single filing was $7.4M of IMVT (221,951 sh across 2 lots, as filed), executed May 28.
The name
IMVTHealthcare · Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Andrew J. Fromkin in IMVT
IMVTSALE
Immunovant, Inc.
$7.4M221,951 sh across 2 lots
Exec May 28
Filed May 29 · 5:30 PM ET IMVTSALE Immunovant, Inc. $129K
6,616 sh × $19.52
Exec Mar 7 2025
Filed Mar 11 2025 · 5:30 PM ET